Kathleen R Blazer
Overview
Explore the profile of Kathleen R Blazer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1390
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Milne R, Kuchenbaecker K, Michailidou K, Beesley J, Kar S, Lindstrom S, et al.
Nat Genet
. 2017 Oct;
49(12):1767-1778.
PMID: 29058716
Most common breast cancer susceptibility variants have been identified through genome-wide association studies (GWAS) of predominantly estrogen receptor (ER)-positive disease. We conducted a GWAS using 21,468 ER-negative cases and 100,594...
12.
Slavin T, Blazer K, Weitzel J
J Clin Oncol
. 2016 Nov;
34(34):4061-4063.
PMID: 27863196
No abstract available.
13.
Blazer K, Slavin T, Weitzel J
JAMA Oncol
. 2016 Feb;
2(6):723-4.
PMID: 26869327
No abstract available.
14.
Slavin T, Niell-Swiller M, Solomon I, Nehoray B, Rybak C, Blazer K, et al.
Front Oncol
. 2015 Dec;
5:271.
PMID: 26697406
[This corrects the article on p. 208 in vol. 5, PMID: 26484312.].
15.
Blazer K, Nehoray B, Solomon I, Niell-Swiller M, Culver J, Uman G, et al.
Genet Test Mol Biomarkers
. 2015 Nov;
19(12):657-65.
PMID: 26539620
Background: Advances in next-generation sequencing (NGS) technologies are driving a shift from single-gene to multigene panel testing for clinical genetic cancer risk assessment (GCRA). This study explored perceptions, experiences, and...
16.
Slavin T, Niell-Swiller M, Solomon I, Nehoray B, Rybak C, Blazer K, et al.
Front Oncol
. 2015 Oct;
5:208.
PMID: 26484312
Background: Multigene panels can be a cost- and time-effective alternative to sequentially testing multiple genes, especially with a mixed family cancer phenotype. However, moving beyond our single-gene testing paradigm has...
17.
Peterlongo P, Chang-Claude J, Moysich K, Rudolph A, Schmutzler R, Simard J, et al.
Cancer Epidemiol Biomarkers Prev
. 2014 Oct;
24(1):308-16.
PMID: 25336561
Background: BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of...
18.
Villarreal-Garza C, Alvarez-Gomez R, Perez-Plasencia C, Herrera L, Herzog J, Castillo D, et al.
Cancer
. 2014 Sep;
121(3):372-8.
PMID: 25236687
Background: Frequent recurrent mutations in the breast and ovarian cancer susceptibility (BRCA) genes BRCA1 and BRCA2 among Hispanics, including a large rearrangement Mexican founder mutation (BRCA1 exon 9-12 deletion [ex9-12del]),...
19.
MacDonald D, Deri J, Ricker C, Perez M, Ogaz R, Feldman N, et al.
Fam Cancer
. 2012 Jun;
11(3):449-58.
PMID: 22678665
A patient/family-centered conference was conducted at an underserved community hospital to address Latinas' post-genetic cancer risk assessment (GCRA) medical information and psychosocial support needs, and determine the utility of the...
20.
Espenschied C, MacDonald D, Culver J, Sand S, Hurley K, Banks K, et al.
J Cancer Educ
. 2012 May;
27(3):467-77.
PMID: 22610836
This paper describes the use of action research in a patient conference to provide updated hereditary cancer information, explore patient and family member needs and experiences related to genetic cancer...